Lipoprotein(a): Novel target and emergence of novel therapies to lower cardiovascular disease risk

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 2, 2016, Pages 157-164

  Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense Oligonucleotides; Aortic Stenosis; Cardiovascular Disease; Diabetes Mellitus; Lipoprotein(a)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; LIPOPROTEIN A; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ANTISENSE THERAPY; AORTA STENOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; THROMBOSIS; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; DOWN REGULATION; DRUG DEVELOPMENT; DYSLIPIDEMIAS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; DOWN-REGULATION; DRUG DISCOVERY; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASE 9; RISK ASSESSMENT; RISK FACTORS; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84960093799     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000237     Document Type: Review

References (48)

1. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
2. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31:2844-2853.
3. White J, Varvel S, Tsimikas S. Abstract 14669: prevalence of elevated Lp(a) levels in 629 858 subjects from a referral laboratory population in the United States. Circulation 2015; 132:A14669.
4. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008; 117:176-184.
5. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
6. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
7. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Int Med 2013; 273:6-30.
8. Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2030-2036.
9. Tregouet DA, Konig IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41:283-285.
10. Ober C, Nord AS, Thompson EE, et al. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res 2009; 50:798-806.
11. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Gen 2010; 3:39-46.
12. Deo RC, Wilson JG, Xing C, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One 2011; 6:e14581.
13. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet 2011; 4:565-573.
14. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45:1345-1352.
15. Consortium CAD, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45:25-33.
16. ODonoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014; 63:520-527.
17. Albers JJ, Slee A, OBrien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62:1575-1579.
18. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial
19. Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997; 52:254-261.
20. Hiraga T, Kobayashi T, Okubo M, et al. Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 1995; 18:241-244.
21. Kollerits B, Auinger M, Reisig V, et al. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care 2006; 29:1661-1663.
22. Saely CH, Koch L, Schmid F, et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest 2006; 36:91-97.
23. Qi Q, Workalemahu T, Zhang C, et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012; 33: 325-334.
24. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110:1406-1412.
25. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41:360-370.
26. Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56:1252-1260.
27. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: A Mendelian randomisation study. Lancet Diabetes Endocrinol 2013; 1:220-227.
28. Ye Z, Haycock PC, Gurdasani D, et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes 2014; 63:332-342.
29. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein( a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15:167-174.
30. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009; 119:1711-1719.
31. Rainwater DL, Haffner SM. Insulin and 2-h glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18:1335-1341.
32. Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 1999; 42:41-44.
33. Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 2015; 66:1236-1246.
34. Taleb A, Witztum JL, Tsimikas S.Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med 2011; 5:673-694.
35. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128:2567-2576.
36. Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res 2012; 53:2405-2412.
37. Ooi EM, Watts GF, Chan DC, et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and apoB-100-containing lipoproteins in statin-Treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015; 35:2686-2693.
38. Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 2015; 35:689-699.
39. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118:743-753.
40. Muller N, Schulte DM, Turk K, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res 2015; 56:1034-1042.
41. Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-Thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation 2013; 128:962-969.
42. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9monoclonal antibody evolocumab (AMG145): A pooledanalysis ofmore than 1300 patients in 4 phase II trials. J AmColl Cardiol 2014; 63:1278-1288.
43. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203:371-376.
44. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein( a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283:1845-1852.
45. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011; 57:1611-1621.
46. Graham MJ, Viney N, Crooke R, Tsimikas S. Antisense inhibition of apolipoprotein( a) to lower plasma lipoprotein(a) levels in humans. J Lipid Res 2015.
47. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein( a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386:1472-1483.
48. Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-Acetyl galactosamine improves potency 10-fold in mice. Nucl Acids Res 2014; 42:8796-8807.